Skip to content

Yoga Nidra in Resistant Hypertension

Effect of Yoga Nidra on blood pressure in patients with Resistant Hypertension: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023365
Enrollment
112
Registered
2020-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Yoga Nidra: The patients in the intervention group will practice Yoga Nidra technique in addition to one health education session on the management of Hypertension and will continue the

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with resistant hypertension as per the diagnostic criteria devised by American Heart Association (AHA) [i.e. patients who fail to achieve target blood pressure of =3 antihypertensive medications] 2. Willingness to participate in the study by signing written informed consent

Exclusion criteria

Exclusion criteria: 1. Patient with the history of Pseudo-Resistant Hypertension (non-adherence to medication, high salt intake, white coat hypertension, improper BP measurement), and Resistant Hypertension due to secondary causes like common substance (antidepressants such as venlafaxine, phenylephrine, glucocorticoids, erythropoietin, calcineurin inhibitors, hormonal contraceptives, cocaine, amphetamine, ecstasy) Obstructive Sleep Apnoea, Obesity, Hyperaldosteronism, Pheochromocytoma 2. Patients who are currently enrolled in any other research study 3. Patients with other cardiovascular conditions like untreated coronary artery disease, heart failure, rheumatic heart disease and congenital heart disease 4. Patients with Chronic Kidney Disease (GFR >/ =3 with presence of markers of kidney damage) 5. Patients with hepatic, pulmonary, endocrinal, neurological, psychiatric disorders and/or complications

Design outcomes

Primary

MeasureTime frame
Assessment of systolic blood pressure level using 24-hours Ambulatory Blood Pressure Monitoring (ABPM)Timepoint: Baseline and at 6 month

Secondary

MeasureTime frame
Assessment of autonomic changes by measuring Heart Rate Variability (HRV) using Holter monitorTimepoint: Baseline and at 6 month;Assessment of Depression, Anxiety and Stress level using DASS-21 QuestionnaireTimepoint: Baseline and at 6 month;Assessment of Quality of Life using SF-36 QuestionnaireTimepoint: Baseline and at 6 month

Countries

India

Contacts

Public ContactDr S Ramakrishnan

All India Institute of Medical Sciences, New Delhi

ramaaiims@gmail.com011-26549326

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026